OncoPharm

Trying to make sense of the limited information put out via Press Release the last 2 weeks for mobocertinib, pembrolizumab + enfortumab vedotin, nivolumab, and more.

From the Foundations of OncoPharm archives - the history and groundbreaking STI 571 (imatinib).

Explore the landmark 2003 study on carboplatin-paclitaxel in ovarian cancer and its implications for treatment today. Discover how this trial outperformed prior standards, particularly in progressing-free and overall survival rates. Learn about the pharmacologic differences between carboplatin and cisplatin, alongside safety profiles that reveal important toxicities. The discussion also highlights the addition of bevacizumab, which may enhance patient outcomes but leaves some questions about overall survival. A fascinating dive into cancer treatment evolution!

An experimental drug for EGFRm NSCLC, patritumab deruxtecan (HER3-DXd), raises some eyebrows and a new agent is FDA-approved for hematopoietic stem cell mobilization (motixafortide).

You read it in every solid tumor paper - RECIST - criteria. This Pod discusses some of the details of the Response Evaluation in Solid Tumors (RECIST) criteria along with the pros and cons of its use - including a modification of the criteria for use with immunotherapy.

Empiric dose reductions for variant DPYD alleles isn't necessarily new, but the outcomes of patients treated with those dose reductions isn't well described. Dutch researchers provide some much needed evidence. Link: https://pubmed.ncbi.nlm.nih.gov/?term=37639651 Is there a role for ICIs in dMMR/MSI-h pancreatic cancer? This retrospective says, uh maybe probably. Link: https://pubmed.ncbi.nlm.nih.gov/?term=37625102

Delve into the innovative world of nab-paclitaxel, a game-changing formulation that enhances drug delivery and reduces hypersensitivity reactions. Discover its biochemical mechanisms and the key advantages it holds over traditional paclitaxel. The discussion also highlights its diverse applications in cancer treatment, making it a pivotal topic in modern oncology.

A combination product is now available of niraparib + abiraterone for use in mCRPC. Another BCMA-CD3 agent is approved for r/r multiple myeloma and melphalan hepatic arterial infusion for metastatic uveal melanoma is approved.

Talquetamab is approved for r/r multiple myeloma and the STOP-CA trials asks if atorvastatin can prevent anthracycline cardiotoxicity. STOP-CA: https://jamanetwork.com/journals/jama/fullarticle/2807988

The Ruby trial leads to an FDA approval for dostarlimab + chemo in advanced/recurrent endometrial cancer, but only dMMR/MSI-H patients. Quizartinib's label and REMS program provide some clear, but concerning, warnings about its toxicity.